Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With
07 5월 2008 - 4:00AM
PR Newswire (US)
Pharmacogenetic Findings May Lead to Individualized Treatment for
Schizophrenia WASHINGTON, MAY 6 /PRNewswire-FirstCall/ -- Data
presented today on Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA)
investigational drug candidate, iloperidone, included its 4-week,
short-term Phase III trial, as well as a pooled analysis of three
long-term, 52-week trials, studying the efficacy and safety of
iloperidone. Iloperidone is a 5HT2/D2 antagonist ("atypical")
antipsychotic currently under review by the U.S. Food and Drug
Administration (FDA) for the treatment of schizophrenia. Additional
data were presented identifying genetic markers that may help
predict response to iloperidone, which Vanda believes could lead to
unique, individualized treatment for schizophrenia. These data were
presented today at the 161st American Psychiatric Association (APA)
Annual Meeting in Washington, D.C. "The data from the clinical
trials studying the efficacy and safety of iloperidone suggest that
iloperidone could be a useful long-term treatment option for people
with schizophrenia," said Peter Weiden, M.D., Director of the
Psychosis Program of the Department of Psychiatry at the University
of Illinois at Chicago and one of the leading experts on adverse
events of antipsychotic medications. The data presented are part of
the New Drug Application (NDA) submitted and currently under review
by the FDA and demonstrate that iloperidone is effective in the
short-term treatment of schizophrenia and that iloperidone is
non-inferior to haloperidol in long-term maintenance measured as
time to relapse over 52 weeks. In these trials, iloperidone showed
short- and long- term safety with respect to movement disorders and
metabolic effects, including extrapyramidal symptoms (EPS) and
akathisia, as well as blood glucose, body weight and lipid
profiles. Schizophrenia is a chronic, severe and disabling disorder
that affects approximately one percent of Americans. A high degree
of treatment dissatisfaction remains among patients with
schizophrenia and the physicians who treat them. The recent CATIE
(Clinical Antipsychotic Trials of Intervention Effectiveness)
study, conducted by the National Institute of Mental Health (NIMH)
and reported in the New England Journal of Medicine, evaluated
several antipsychotic medications and revealed that 74 percent of
patients taking antipsychotics discontinued treatment within 18
months, primarily because of insufficient efficacy and tolerability
issues(*). Iloperidone's Efficacy Profile In data presented on a
4-week Phase III trial, iloperidone (24 mg/day) was more effective
than placebo in the short-term treatment of acutely exacerbated
schizophrenia, providing relief across both positive and negative
symptom domains. Iloperidone showed significantly greater
improvement than placebo in PANSS-T(1) scores, as did ziprasidone
(-12.0; p=0.006 for iloperidone vs. placebo and -12.3; p=0.012 for
ziprasidone vs. placebo); these improvements were seen in both the
mean PANSS-P and PANSS-N(2) subscales. Additionally, BPRS(3) scores
improved significantly with iloperidone (-7.4; p=0.013) and
ziprasidone (-7.2; p=0.042) versus placebo; and CGI-S(4) scores
also significantly improved with iloperidone (-0.65; p=0.007) and
ziprasidone (-0.67; p=0.013) versus placebo(1). In data presented
from three prospective, 52-week Phase III trials comparing a dose
range of iloperidone (4-16 mg/day given BID, n=981) to haloperidol
(5-20 mg/day given BID, n=300), iloperidone was statistically non-
inferior to haloperidol in time to relapse (89.8 days with
iloperidone vs. 101.8 days with haloperidol; p=0.764).
Additionally, the three trials found similar relapse rates and
improvements in CGI-C(5) and PANSS-T scores. Iloperidone's Safety
Profile Data presented from a 4-week Phase III trial demonstrated
that rates of worsened BAS(6) total score was similar between
iloperidone and placebo (8.3% vs. 11.6%; p=0.302) but significantly
higher with ziprasidone versus placebo (26.0% vs. 11.6%; p
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024